Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now?

McKesson’s Zacks Rank is #2 (Buy), supported by modestly rising consensus estimates: current- and next-fiscal-year EPS estimates are $44.73 and $49.93, each up 0.2% over the past 30 days. Last quarter, revenue was $105.38 billion (+7.7% year over year) and EPS was $9.93, beating consensus by 0.95% and 5.19%, respectively; EPS beat estimates in all four trailing quarters. Shares gained 3.7% over the past month, and Zacks gives the stock a B valuation grade, indicating a discount to peers.

Analysis

The bullish signal is weaker than the headline-style framing suggests: forward estimates have barely moved, so the rating rests more on the existing earnings trajectory than on a newly improving outlook. For a low-margin distributor, reported sales growth is a poor proxy for value creation; drug-price inflation and mix can lift revenue without comparable profit growth. The key underwriting variables are therefore gross-profit dollars, specialty distribution growth, generic economics, and cash conversion—not top-line growth alone.

McKesson’s scale and distribution infrastructure can benefit as care shifts toward specialty drugs, but that is not an unchallenged moat: Cencora and Cardinal Health compete for the same manufacturer and provider economics. A sharper pricing environment or customer retention concessions could absorb volume gains across the group. Working-capital needs also make cash generation a useful check on whether EPS growth is translating into shareholder value.

Near term, estimate stability and prior earnings beats support downside resilience, but the recent relative strength raises the bar for a fresh positive surprise. Over the next 1–3 months, focus on guidance and evidence that specialty mix and gross-profit growth are carrying earnings. Over 6–18 months, the thesis depends on durable specialty economics and cash conversion. The contrarian risk is that investors treat distributor revenue growth as structural earnings acceleration; absent upward estimate revisions, that interpretation may be overextended. Verify current valuation multiples, segment profit trends, and cash flow before adding.

Key Decisions for Investors

• Do not chase MCK solely on the positive rating or revenue growth. Maintain existing exposure; consider a staged add only after a pullback or a clear upward revision to earnings guidance.
• For a 1–3 month catalyst, monitor gross profit and operating profit growth against revenue, specialty distribution trends, and operating cash flow. Strong sales with weak profit conversion would falsify the bullish read.
• Reassess after the next earnings report: trim or avoid adding if guidance is reduced, cash conversion deteriorates, or estimate revisions turn negative; upgrade conviction if specialty-related profit growth and cash generation both improve.
• Before sizing a relative-value position against Cencora or Cardinal Health, compare current valuation, segment growth, and cash conversion on a consistent basis; those data are not supplied here.